Your Patients May Want More Than Efficacy1-3


With quantity of life increasing in ALK+ mNSCLC, quality of life is increasingly important1-3

  • Patients are being diagnosed younger (median age 51 years old) and staying on treatment longer4
  • Median overall survival for Stage IV ALK+ mNSCLC is 6.75 years3
  • More time on therapy increases the importance of efficacy in the brain, a reduced pill burden, and long term tolerability1,3,5,6

Which of these other considerations is a top priority for you?

Step 1 of 2
Category 1, Preferred NCCN Recommendation.

National Comprehensive Cancer Network® (NCCN®): recommends brigatinib as a Category 1, preferred first-line treatment option for ALK+ metastatic NSCLC7,a,b,c 

ALUNBRIG® (brigatinib) has demonstrated long-term tolerability in the ALTA 1L trial8,9

The efficacy and safety of ALUNBRIG was studied in ALTA 1L, a Phase 3, randomized, open-label, multicenter clinical trial in adult patients (N=275) with advanced ALK+ mNSCLC who had not previously received an ALK-targeted therapy. Patients were randomized (1:1) to receive ALUNBRIG (n=137) or crizotinib (n=138). The major efficacy outcome measure was progression free survival according to RECIST v1.1 as evaluated by a blinded independent review committee (BIRC).

  • Median follow-up in the ALUNBRIG arm was 40.4 months
  • Median duration of treatment with ALUNBRIG was 24.3 months
  • Median relative dose intensity with ALUNBRIG was 97%
  • The most common serious adverse reactions were pneumonia (4.4%), ILD/pneumonitis (3.7%), pyrexia (2.9%), dyspnea (2.2%), pulmonary embolism (2.2%), and asthenia (2.2%). Fatal adverse reactions occurred in 2.9% of patients and included pneumonia (1.5%), cerebrovascular accident (0.7%), and multiple organ dysfunction syndrome (0.7%)

Discover how ALUNBRIG impacted patients' quality of life10

aWhen an ALK rearrangement is discovered prior to first-line systemic therapy.7
bThe NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
cSee the NCCN Guidelines® for detailed recommendations, including other preferred treatment options.

ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; CNS, central nervous system; mNSCLC, metastatic NSCLC; NSCLC, non-small cell lung cancer; NCCN, National Comprehensive Cancer Network.